Company Filing History:
1 out of 16,338 
1 out of 12 Years Active: 2007-2010
Title: Sean M Dalziel: Innovator in Pharmaceutical Compounds
Introduction
Sean M Dalziel is a notable inventor in the field of pharmaceuticals, particularly recognized for his work on benzimidazole-carboxamide compounds. His innovative contributions focus on the development of compounds that act as 5-HT4 receptor agonists, which have potential therapeutic applications.
Latest Patents
Sean M Dalziel holds a patent related to "Benzimidazole-Carboxamide Compounds As 5-Ht4 Receptor Agonists." This invention pertains to compounds of formula (I), where R1 and X are defined in the specification. The patent also covers pharmaceutically acceptable salts, solvates, or stereoisomers of these compounds. Additionally, it includes pharmaceutical compositions that comprise such compounds, methods for treating diseases associated with 5-HT4 receptor activity, and processes for preparing these compounds. Furthermore, the invention discusses crystalline forms of the compound of formula (I).
Career Highlights
Sean M Dalziel is currently associated with Theravance, Inc., where he continues to contribute to the advancement of pharmaceutical innovations. His work is pivotal in exploring new therapeutic avenues for various medical conditions.
Collaborations
Sean has collaborated with notable colleagues, including Robert Murray Mckinnell and Roland Gendron, who share a commitment to advancing pharmaceutical research and development.
Conclusion
Sean M Dalziel's contributions to the field of pharmaceuticals, particularly through his innovative work on 5-HT4 receptor agonists, highlight his role as a significant inventor. His ongoing efforts at Theravance, Inc. continue to pave the way for new therapeutic solutions.